Valuation dashboard for Amylyx Pharmaceuticals, Inc. (AMLX) with P/E N/A, P/B 13.58, EV/EBITDA -23.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $29.20 (closing price, November 3, 2026), AMLX has negative trailing earnings (P/E not meaningful) and an ROE of -52.92%. Market capitalisation stands at $3.7B.
Balance sheet quality for AMLX: debt-to-equity ratio of 0.02, current ratio of 12.12 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 13.58 |
| EV / EBITDA | -23.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.7B | 13.58 | -52.9% | |
| IONS | Ionis Pharmaceuticals, Inc. | $6.7B | 15.51 | -110.8% | |
| PRAX | Praxis Precision Medicines, Inc. | $7.8B | 5.95 | -34.1% | |
| DNLI | Denali Therapeutics Inc. | $3.1B | 3.96 | -34.0% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 12.93 | -39.2% |
Price
| Price | $29.20 (closing price, November 3, 2026) |
| Market Cap | $3.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -52.92% |
| Return on Invested Capital | -66.32% |
| Return on Assets | -57.49% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: IONS · PRAX · DNLI · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of AMLX: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks